CSIMarket
 
Entrada Therapeutics Inc   (TRDA)
Other Ticker:  
 
 
Price: $12.7800 $0.58 4.754%
Day's High: $12.81 Week Perf: 8.67 %
Day's Low: $ 12.09 30 Day Perf: -13.36 %
Volume (M): 112 52 Wk High: $ 18.44
Volume (M$): $ 1,429 52 Wk Avg: $14.69
Open: $12.20 52 Wk Low: $10.62



 Market Capitalization (Millions $) 427
 Shares Outstanding (Millions) 33
 Employees 89
 Revenues (TTM) (Millions $) 129
 Net Income (TTM) (Millions $) 5
 Cash Flow (TTM) (Millions $) 22
 Capital Exp. (TTM) (Millions $) 6

Entrada Therapeutics Inc
Entrada Therapeutics Inc is a clinical-stage biotechnology company that is dedicated to developing transformative therapeutics for various serious diseases. The company's technology platform is focused on utilizing the body's natural cellular uptake mechanisms to deliver large macromolecules, such as proteins and nucleic acids, across biological barriers for targeted intracellular delivery.

Founded in 2018, Entrada Therapeutics is headquartered in Boston, Massachusetts, in the United States, with additional offices in San Diego, California. The company is led by a team of seasoned industry executives, including CEO Dipal Doshi, President and COO Meghna Dasgupta, and CMO James Hamilton.

The company's lead program, ENTR-101, is a potential treatment for cystic fibrosis. ENTR-101 utilizes Entrada's proprietary Endosomal Escape Vehicle (EEV) technology to transport a specially designed protein that corrects the underlying genetic mutation causing cystic fibrosis. This technology allows the protein to enter the cell, bypass molecular barriers and reach its target in the endosome, thus enabling the protein to be fully functional.

In addition to ENTR-101, Entrada has a robust pipeline that includes multiple therapeutic programs in various stages of development. The company is focused on developing therapies for indications where macromolecular therapeutics have the potential to provide significant patient benefit, such as neurodegenerative diseases, genetic disorders, and cancer.

Entrada Therapeutics has developed strategic collaborations with key partners in the biotech industry, including Roche, Ferring Pharmaceuticals, and BMS. These partnerships provide the company with additional funding and resources, as well as important guidance and expertise.

Overall, Entrada Therapeutics is committed to bringing innovative, life-changing therapies to patients in need, by harnessing the power of its unique technology platform and scientific expertise. Their work is poised to have a profound impact on the lives of patients suffering from serious diseases.


   Company Address: One Design Center Place Boston 2210 MA
   Company Phone Number: 520-9158   Stock Exchange / Ticker: NASDAQ TRDA
   


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Entrada Therapeutics Inc

Entrada Therapeutics Inc. Announces Impressive Revenue Growth in Q4 2023

Entrada Therapeutics Inc, a major pharmaceutical preparations company, has recently disclosed its financial results for the fiscal period closing December 31, 2023. The company reported a revenue of $41.848 million for this period, indicating a steady growth from the previous year. However, it also reported a net shortfall of $-30.755 million, which is larger than the shortfall of $-24.629 million recorded a year ago.
In addition to this, Entrada Therapeutics Inc claimed a shortfall of $5.37 million for the fiscal year 2023, along with a revenue of $129.01 million for the same period. This shows that while the company has made progress in generating revenue, it still faces challenges in managing its expenses.

Clinical Study

Entrada Therapeutics Pushes Boundaries in DMD Treatment Research, While Revenue Growth Lags Behind Rivals

Published Wed, Nov 22 2023 12:00 PM UTC



In its ongoing efforts to combat Duchenne Muscular Dystrophy (DMD), Entrada Therapeutics Inc has achieved significant milestones by completing the dosing of the first and second cohorts in its Phase 1 clinical trial for ENTR-601-44-101. This promising development brings new hope to individuals suffering from this devastating rare disease. However, recent financial ...

Entrada Therapeutics Inc

Entrada Therapeutics Inc Reports Strong Revenue Growth of $18.17 Million in Q2 2023, Signaling a Robust Performance



Entrada Therapeutics Inc, a leading biotechnology company, recently released its financial results for the second quarter of 2023. The report highlights a significant improvement in revenue and a narrower net deficit compared to the same quarter in the previous year. This article aims to interpret the facts and provide context to these financial outcomes.
1. Revenue Growth and Improved Performance:
During the span of April to June 30, 2023, Entrada Therapeutics Inc disclosed an impressive revenue of $18.17 million. This represents a positive sign for the company's financial health, indicating growth and increased sales compared to the previous year.

Entrada Therapeutics Inc

Entrada Therapeutics Inc Reports Revenue of $25.26 Million, Demonstrating Positive Growth Amidst Challenging Market Conditions

Investors in the healthcare industry should take note of Entrada Therapeutics Inc's recent financial performance. The company recorded a cumulative net loss of $-76 million during the 12 months ending in the first quarter of 2023, resulting in a negative ROI of -28.1%.
While the performance may be concerning, it is important to note that 236 other companies within the healthcare sector had a higher ROI. Additionally, Entrada's overall ROI ranking has improved to 2199 in the first quarter of 2023 from 4125 in the fourth quarter of 2022.






 

Entrada Therapeutics Inc's Segments
 
 
• View Complete Report
  Company Estimates  
  Revenue Outlook
Entrada Therapeutics Inc does not provide revenue guidance.

Earnings Outlook
Entrada Therapeutics Inc does not provide earnings estimates.

 
Geographic Revenue Dispersion




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com